Sale!

Novartis letrozole

For the adjuvant therapy of postmenopausal women with early breast cancer and a hormone receptor positive, letrozole from Novartis is suggested. Femara is approved for the extended adjuvant treatment of early breast cancer in postmenopausal women who have undergone adjuvant tamoxifen therapy for five years.

2,750.00 2,500.00

Category:

Reviews

There are no reviews yet.

Be the first to review “Novartis letrozole”

Your email address will not be published. Required fields are marked *